These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9110460)

  • 41. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldose reductase inhibitors and cataract.
    Crabbe MJ
    Int Ophthalmol; 1991 Jan; 15(1):25-36. PubMed ID: 1901300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Aldose-reductase inhibitors and cataract formation (author's transl)].
    Keller G; Leuenberger PM
    Klin Monbl Augenheilkd; 1980 Apr; 176(4):514-5. PubMed ID: 6775130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
    Maccari R; Ottanà R
    J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
    Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
    Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
    Giannoukakis N
    Curr Opin Investig Drugs; 2006 Oct; 7(10):916-23. PubMed ID: 17086937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [SG-210].
    Akira T; Naka H
    Nihon Rinsho; 1997 Nov; 55 Suppl():216-20. PubMed ID: 9434470
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
    Kador PF; Inoue J; Secchi EF; Lizak MJ; Rodriguez L; Mori K; Greentree W; Blessing K; Lackner PA; Sato S
    Exp Eye Res; 1998 Aug; 67(2):203-8. PubMed ID: 9733586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Sibley EO; McCann EE; Combs KJ; Flam B; Sawicki DR; Sabetta A; Carrington A; Sredy J; Howard E; Mitschler A; Podjarny AD
    Bioorg Med Chem; 2004 Nov; 12(21):5661-75. PubMed ID: 15465344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.
    Jannapureddy S; Sharma M; Yepuri G; Schmidt AM; Ramasamy R
    Front Endocrinol (Lausanne); 2021; 12():636267. PubMed ID: 33776930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
    Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medical treatment of cataract.
    Toh T; Morton J; Coxon J; Elder MJ
    Clin Exp Ophthalmol; 2007; 35(7):664-71. PubMed ID: 17894689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-Activity Relationship Study Reveals Benzazepine Derivatives of Luteolin as New Aldose Reductase Inhibitors for Diabetic Cataract.
    Sebastian J
    Curr Drug Discov Technol; 2016; 13(3):152-163. PubMed ID: 27396410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose.
    Kador PF; Betts D; Wyman M; Blessing K; Randazzo J
    Am J Vet Res; 2006 Oct; 67(10):1783-7. PubMed ID: 17014334
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of aldose reductase by Aegle marmelos and its protective role in diabetic cataract.
    Sankeshi V; Kumar PA; Naik RR; Sridhar G; Kumar MP; Gopal VV; Raju TN
    J Ethnopharmacol; 2013 Aug; 149(1):215-21. PubMed ID: 23827758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discoveries in research on diabetic keratopathy.
    Cisarik-Fredenburg P
    Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The role of polyol pathways in formation of diabetic cataracts].
    Sabasiński K; Andrzejewska-Buczko J
    Klin Oczna; 1997; 99(6):401-4. PubMed ID: 9685789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
    Karasova MJ; Prnova MS; Stefek M
    Pharmazie; 2014 Oct; 69(10):747-51. PubMed ID: 25985564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The inhibitory effect of Isoflavones isolated from Caesalpinia pulcherrima on aldose reductase in STZ induced diabetic rats.
    Kumar MP; Sankeshi V; Naik RR; Thirupathi P; Das B; Raju TN
    Chem Biol Interact; 2015 Jul; 237():18-24. PubMed ID: 25986969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aldose reductase: black sheep or skeleton in the cupboard?
    Crabbe MJ; Goode D; Wolff SP
    Nat Struct Biol; 1996 Aug; 3(8):659-61. PubMed ID: 8756319
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.